Axonics, Inc. (AXNX)


+0.66 (+1.20%)
Symbol AXNX
Price $55.84
Beta 0.423
Volume Avg. 0.70M
Market Cap 2.818B
Shares () -
52 Week Range 47.59-77.2
1y Target Est -
DCF Unlevered AXNX DCF ->
DCF Levered AXNX LDCF ->
ROE -7.67% Neutral
ROA -4.96% Neutral
Operating Margin -
Debt / Equity -16.20% Neutral
P/E -87.25 Strong Sell
P/B -149.61 Strong Sell


Consensus EPS

Upgrades & Downgrades

Latest AXNX news

Mr. Raymond W. Cohen
Medical Devices
NASDAQ Global Select

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.